Mammary Cell News Volume 14.23 | Jun 23 2022

    By
    Bob
    -
    0
    56






    2022-06-23 | MCN 14.23


    Mammary Cell News by STEMCELL Technologies
    Vol. 14.23 – 23 June, 2022
    TOP STORY

    DNA Minicircle as a Novel STAT3 Decoy Oligodeoxynucleotide Endowed with Anticancer Activity in Triple Negative Breast Cancer

    Investigators described the in vitro and in vivo activity of formulated 95 bp minicircles bearing one or several STAT3 binding sequences in TNBC.
    [Molecular Therapy-Nucleic Acids]

    AbstractFull ArticleGraphical Abstract

    Facts Vs. claims. Three scientists peer reviewed a life science vendor to get to the truth. See for yourself.
    PUBLICATIONSRanked by the impact factor of the journal

    Phenazine Derivatives Attenuate the Stemness of Breast Cancer Cells through Triggering Ferroptosis

    Researchers focused on the compounds without affecting cell viability and screened out three potential compounds that could significantly attenuate the stemness of breast cancer cells, as evident by the decrease of stemness marker expression.
    [Cellular and Molecular Life Sciences]

    Abstract

    Combined Inhibition of EZH2 and ATM Is Synthetic Lethal in BRCA1-Deficient Breast Cancer

    To validate the role of enhancer of zeste homolog 2 (EZH2) as a therapeutic target and to identify new synergistic drug combinations, scientists performed a high-throughput drug combination screen in various cell lines derived from BRCA1-deficient and -proficient mouse mammary tumors.
    [Breast Cancer Research]

    Full Article

    Cryptolepine Suppresses Breast Adenocarcinoma via Inhibition of HIF-1 Mediated Glycolysis

    Investigators revealed that cryptolepine could effectively suppress the process of hypoxia-inducible factor-1α (HIF-1α) mRNA translation rather than transcription.
    [Biomedicine & Pharmacotherapy]

    Full ArticleGraphical Abstract

    Breast Cancer Cells Mediate Endothelial Cell Activation, Promoting Von Willebrand Factor Release, Tumor Adhesion and Transendothelial Migration

    Researchers highlighted the significant crosstalk between tumor cells and the endothelium, including increased von Willebrand Factor secretion, which may have contributed to tumor metastasis.
    [Journal of Thrombosis and Haemostasis]

    AbstractFull Article

    Long Noncoding RNA ST8SIA6-AS1 Promotes Cell Proliferation and Metastasis in Triple-Negative Breast Cancer by Targeting miR-145-5p/CDCA3 to Inactivate the p53/p21 Signaling Pathway

    ST8SIA6-AS1 displayed a higher expression in TNBC cells. Silencing ST8SIA6-AS1 impaired cell proliferation, cell cycle progression, migration, and invasion in vitro, and slowed tumor growth in vivo.
    [Environmental Toxicology]

    Abstract

    MORC2/β-Catenin Signaling Axis Promotes Proliferation and Migration of Breast Cancer Cells

    The authors reported that the chromatin remodeler microrchidia 2 (MORC2) expression positively correlated with β-catenin expression in breast cancer cell lines and patients.
    [Medical Oncology]

    Abstract

    Targeting LIPA Independent of Its Lipase Activity Is a Therapeutic Strategy in Solid Tumors via Induction of Endoplasmic Reticulum Stress

    Investigators defined lysosomal acid lipase A (LIPA) as a viable molecular target in TNBC and identified a stereospecific small molecule that bound LIPA.
    [Nature Cancer]

    Full ArticlePress Release

    View tips on how to share lab duties effectively.
    REVIEWS

    Recent Insights into the Effects of Metabolism on Breast Cancer Cell Dormancy

    The authors highlight that the metabolic states/shifts of dormant breast cancer (BC) cells seem to be dependent on different BC subtypes and receptor status; however, more work needs to be done to fully map these differences.
    [British Journal of Cancer]

    Full Article
    INDUSTRY AND POLICY NEWS

    Susan G. Komen® Invests $21.7 Million In Research Focused on Improving Outcomes For Breast Cancer Patients

    Susan G. Komen® has awarded $21.7 million to fund 48 new research projects at 26 distinguished academic medical institutions in the US that are focused on improving patient outcomes – particularly for people with the most aggressive breast cancers, or who have experienced a recurrence or metastasis.
    [Susan G. Komen®]

    Press Release
    FEATURED EVENT

    Cell Bio 2022

    December 3 – 7, 2022
    Washington, DC, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Training Fellow – Patient Derived Models

    The Institute of Cancer Research – London, England, United Kingdom

    Research Technologist – Pediatrics

    Pennsylvania State University – State College, Pennsylvania, United States

    Research Associate – Cancer Biology

    University of Bristol – Bristol, England, United Kingdom

    Analytical Scientist – Molecular Oncology

    Institute of Cancer Research – London, England, United Kingdom

    Academic Surgical Pathologist – Pathology and Laboratory Medicine

    University of Vermont – Burlington, Vermont, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mammary Cell News Twitter